Patients are critical in helping to transform optimism into reality by Ken Kahtava, Chief Business Officer, FSHD Society Breakthroughs in FSHD research have identified the primary mechanism that causes FSHD…. Read More »
(Cautious) optimism in FSHD drug development
Promising findings from Avidity’s myotonic dystrophy trial
A major breakthrough for the field of RNA therapeutics Avidity Biosciences announced today that its investigational treatment for myotonic dystrophy type 1 (DM1), called AOC 1001, can be delivered into… Read More »
Springboards to the future
Everything we do propels us faster toward treatments and a cure We often speak of “filling potholes” and “overcoming obstacles” toward treatments and cures, but what the FSHD Society has… Read More »
Using our leverage
A few years ago, we told our donors that a gift to the FSHD Society “is one of the most powerful investments you will ever make to advance medical research.”… Read More »
$3.4 million to speed us on our journey (Part 3)
The foundations on which drug development happens “Infrastructure is basic physical and organizational structures…needed for the operation of a society or enterprise.” —Oxford Dictionary In a rare condition like FSHD, it’s… Read More »